German Government Cuts Funding for Long Covid Research
The latest federal budget includes almost no new funding for Long Covid research, a decision that scientists criticize as short-sighted and potentially costly for the economy. Experts estimate that the long-term economic consequences could reach billions of euros.
Shrinking Budgets Despite Promises
In July, Health Minister Nina Warken (CDU) had expressed determination to support Long Covid research, promising substantial financial backing. However, the 2026 draft budget tells a different story. New research funding has been cut dramatically—from around €140–150 million in the previous legislative period under former Minister Karl Lauterbach (SPD) to only about €16 million.
Of this, €15 million is earmarked for care models for children and adolescents with Long Covid, and €200,000 for information and counseling services. Although Long and Post Covid are still listed as research priorities, the total health research budget of €41.47 million also covers seven other major areas, such as women’s health, digitalization, and prevention. These are not new funds but continuations of existing programs, and even this amount has been slightly reduced compared to last year (€43.08 million).
When asked about the lack of new funding, the Health Ministry referred vaguely to €118 million from ongoing programs but did not explain why no new money was allocated despite previous public promises.
Limited Support from the Research Ministry
The Federal Ministry of Education and Research (BMBF), led by Minister Dorothee Bär (CSU), is responsible for developing new treatments and medications. Although about €187 million is planned for “widespread diseases” in 2026—including cancer, heart disease, diabetes, dementia, and mental health—Long Covid is not listed separately. It is only indirectly supported through broader programs such as the National Network of University Medicine and ME/CFS research. Sources suggest that roughly €16 million of this total will benefit Long Covid projects.
Economic Costs and Health Consequences
According to the ME/CFS Research Foundation and partners, Long Covid and ME/CFS have already caused economic damages of over €250 billion in Germany since the pandemic began. Annual costs could reach €63 billion—about 1.5% of Germany’s GDP.
Economist Alexander Häring from the RWI-Leibniz Institute warns that cutting research will lead to higher long-term costs, as recovery often takes years and a lack of research slows the development of treatments and rehabilitation. Without government support, foundations and private institutions would have to fill the gap, though this is not a sustainable solution.
High Patient Numbers and Unmet Medical Needs
As of 2024, approximately 871,000 people in Germany were living with Long Covid and 650,000 with ME/CFS. Although some drugs have been approved for use, they were originally developed for other diseases. There is still no specific medication or therapy designed for Long Covid.
The need for research remains urgent, as each new infection increases the risk of developing the condition, and the social and psychological toll on patients continues to grow.